Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ISIS 416858 · 2 trials · 1 indication
MB was defined as one of the following: Fatal bleeding; symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular if in a major joint, or pericardial, or intramuscular with compartment syndrome, clinically overt bleeding leading to transfusion of greater than or equal to (\>=) 2 units of packed red blood cells or whole blood or a fall in hemoglobin of 20 grams per liter (g/L) (1.24 millimoles per liter \[mmol/L\]) or more within 24 hours. CRNMB was defined as overt bleeding not meeting the criteria for MB but that resulted, in either medical examination, intervention, or had clinical consequences for a participant.
The safety and tolerability of ISIS 416858 will be evaluated by reviewing frequency and severity of Adverse events (including bleeding events) and use of concomitant medications, changes in vital signs and laboratory evaluations for all patients
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Participants received placebo, subcutaneously, within 2 hours post-dialysis, once weekly from Week 1 (Day 1) through Week 26 of treatment period. |
| Cohort A: ISIS 416858, 200 mg | EXPERIMENTAL | Participants received ISIS 416858, 200 mg, subcutaneously, within 2 hours post-dialysis, once weekly from Week 1 (Day 1) through Week 26 of treatment period. |
| Cohort B: ISIS 416858, 250 mg | EXPERIMENTAL | Participants received ISIS 416858, 250 mg, subcutaneously, within 2 hours post-dialysis, once weekly from Week 1 (Day 1) through Week 26 of treatment period. |
| Cohort C: ISIS 416858, 300 mg | EXPERIMENTAL | Participants received ISIS 416858, 300 mg, subcutaneously, within 2 hours post-dialysis, once weekly from Week 1 (Day 1) through Week 26 of treatment period. |
| PK Cohort | EXPERIMENTAL | A 4-week screening period followed by a 4-week treatment period followed by a 6-week post-treatment evaluation period. Treatment period includes 1 dose of 300 mg ISIS 416858 on Day 1 and again on Day 29. Both doses of Study Drug will be administered subcutaneously (SC). |
| Cohort A | PLACEBO_COMPARATOR | Patients in Cohort A will be randomized to receive either 200 mg ISIS 416858 or placebo. A 2:1 ratio will be used. For Cohort A, the study will include a 4-week screening period and a 12-week treatment period followed by a 12-week post-treatment evaluation period. Cohort A will receive Study Drug (ISIS 416858 or placebo) twice a week during the first 2 weeks, followed by once weekly for the remaining 10 weeks of the treatment period. All doses of Study Drug will be administered subcutaneously (SC) 10 minutes after completion of the hemodialysis treatment. |
| Cohort B | PLACEBO_COMPARATOR | Patients in Cohort B will be randomized to receive either 300 mg ISIS 416858 or placebo. A 2:1 ratio will be used. For Cohort B, the study will include a 4-week screening period and a 12-week treatment period followed by a 12-week post-treatment evaluation period. Cohort B will receive Study Drug (ISIS 416858 or placebo) twice a week during the first 2 weeks, followed by once weekly for the remaining 10 weeks of the treatment period. All doses of Study Drug will be administered subcutaneously (SC) 10 minutes after completion of the hemodialysis treatment. |
| Name | Type | Description |
|---|---|---|
| ISIS 416858 | DRUG | Subcutaneous injection |
| Placebo | DRUG | Subcutaneous injection |
Inclusion Criteria: • End stage renal disease maintained on outpatient hemodialysis at a healthcare center for \> 3 months from screening with hemodialysis at least 3 times per week for a minimum of 9 hours per week of prescribed treatment time and plan to continue this throughout the study. Exclu...
ISIS 416858 is an investigational small molecule being developed for end-stage renal disease (ESRD) in patients on hemodialysis. It is administered subcutaneously and is currently in Phase 2 clinical development. The drug is not approved and remains under investigation for this condition.
ISIS 416858 is being developed by Ionis Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol IONS. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with end-stage renal disease on hemodialysis.
ISIS 416858 is in Phase 2 clinical development. Two Phase 2 trials have been completed, with a total enrollment of 262 participants. The drug is investigational and has not been approved by regulatory authorities for any indication.
ISIS 416858 has been studied in two completed Phase 2 trials: NCT02553889, which enrolled 49 patients in Canada, and NCT03358030, which enrolled 213 patients in Spain. Both trials evaluated subcutaneous administration in adults with end-stage renal disease on hemodialysis.
ISIS 416858 is the primary name used in clinical trials and development. No alternative names have been reported for this drug. It is identified by its NCT numbers in clinical trial registries and by its developer, Ionis Pharmaceuticals.